Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use JADENU safely and effectively. See full prescribing information for JADENU. JADENU® (deferasirox) tablets, for oral use JADENU® Sprinkle (deferasirox) granules, for oral use Initial U.S. Approval: 2005
Medication labelWhy this: Advisory · dailymed-prescription
JADENU is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. JADENU is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L. The safety and efficacy of JADENU when administered with other iron chelation therapy have not been established.
- generic_name
- deferasirox
- product_names
- deferasirox
- ndc
- 0078-0654, 0078-0654-15, 0078-0655, 0078-0655-15, 0078-0656, 0078-0656-15, 0078-0727, 0078-0727-19, 0078-0727-15, 0078-0713, 0078-0713-19, 0078-0713-15, 0078-0720, 0078-0720-19, 0078-0720-15
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en